Topic Lifecycle: Dormant
This topic is currently dormant in the news cycle. It was last covered on Thursday 23 July 2026 and has not appeared in recent broadcasts.
Coverage trend (last 30 days)
How much coverage this topic got from each channel over the past month.
On screen
Stills are sampled automatically at 60-second intervals. Where shown, the still is the nearest available frame from the relevant broadcast segment and is included to show what was on screen during that part of the broadcast. A still may not correspond to the exact second of a quoted phrase.
Recent stories
The latest story timelines linked to this topic, newest activity first.
What was reported
A plain summary of this topic, built from the channels that covered it.
The drug fampridine, which helps people with multiple sclerosis walk more easily, is being made available on the NHS in England. It is described as the first medicine designed to improve walking ability in MS patients. The drug is taken twice a day and works by boosting nerve signals to muscles. According to ITV1, it has been available in Scotland, Wales, and Northern Ireland for years, and its introduction in England is long overdue. The MS Society estimates that 5,000 people will benefit in the first year. The drug is intended for people who have some walking difficulty but are not yet fully reliant on a wheelchair.
Key Claims by Channel
| Claim | Channel 5 | BBC One | ITV |
|---|---|---|---|
| Fampridine is reported as the first drug to help MS patients walk by boosting nerve signals to improve mobility and independence. | · | ||
| The drug is called fampridine. | · | ||
| The drug is taken twice a day. | · | · | |
| Fampridine has been available in Scotland, Wales, and Northern Ireland for years, but not in England until now. | · | ||
| An estimated 5,000 people with MS in England will benefit from the drug in the first year. | |||
| The drug is for people who have started to experience problems with walking but are not yet fully in a wheelchair. | · | · | |
| The drug works by boosting nerve signals to make it easier to move. | · | ||
| The MS Society described the drug as life changing. | · | · | |
| About 40% of patients taking the drug improved their walking speed and distance. | · | · | |
| Fampridine is the only drug licensed to help people with MS with their walking. | · | · | |
| The drug is a twice-daily pill that boosts nerve signals. | · | · | |
| Not everyone responds to the drug. | · | · |
This is a cross-channel consensus summary, not an objective account. Consensus can be uniformly wrong, or omit what only one channel covered.
Timeline
Where this topic appeared. Cells show coverage time and are darker when there was more coverage.